• Background and Design.—
To avoid systemic side effects, topical and intralesional administration of cyclosporine has been used; however, only intralesional administration has been successful. To understand more about the dosing requirements and resultant tissue levels of intralesional cyclosporine, we injected psoriasis plaques in a double-blind fashion with three different concentrations of cyclosporine (17 mg/mL in seven patients, 10 mg/mL in 13 patients, and 2.5 mg/mL in 11 patients) or matching vehicle three times weekly for 4 weeks.
Statistically significant improvement was observed in plaques treated with 17 mg/mL (P =.003) compared with vehicle-treated plaques; the improvements in plaques treated with 10 mg/mL (P=.078) and 2.5 mg/mL (P=.054) achieved marginal statistical significance compared with vehicle treatment. Four weeks after discontinuation of ther
Burns MK, Ellis CN, Eisen D, et al. Intralesional Cyclosporine for PsoriasisRelationship of Dose, Tissue Levels, and Efficacy. Arch Dermatol. 1992;128(6):786–790. doi:10.1001/archderm.1992.01680160070006
Customize your JAMA Network experience by selecting one or more topics from the list below.